CTAD 2023: Roche’s Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab
Ongoing Study Will Expand Before Next Trial Begins
Clinical efficacy data, collected as exploratory endpoints, were not reported at CTAD • Source: Shutterstock 
